The board of directors of pharmaceutical company Allergan plc (NYSE:AGN) declared dividend of USD0.74 per ordinary share for the fourth quarter of 2019, the company revealed on Friday.
This cash dividend is payable on 13 December 2019 to shareholders of record at the close of business as of 13 November 2019.
Headquartered in Dublin, Ireland, Allergan is focused on developing, manufacturing and commercialising branded pharmaceutical, device, biologic, surgical and regenerative medicine products for patients around the world.
In addition, the company markets a portfolio of leading brands and best-in-class products primarily focused on four key therapeutic areas including medical aesthetics, eye care, central nervous system and gastroenterology.
NFL Biosciences and McLean Hospital collaborate to advance NFL-101 mechanism research
Neuraxpharm launches Neuraxpharm Australia
Zhimeng Biopharma's CB03-154 ALS Phase 2/3 study receives Chinese clinical trial approval
Mycovia Pharmaceuticals reports first participant enrolled in Phase 2 cryptococcal meningitis study
Estrella Immunopharma initiates second cohort in EB103 trial for advanced B-cell lymphomas
Dizal to present promising data in CLL, DLBCL and EGFR-Mutant NSCLC at ASCO 2025
EXACT Therapeutics secures UK patent for non-invasive brain drug delivery technology